Doxycycline vs Isotretinoin for Acneiform Eruptions of TKI
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Tyrosine Kinase inhibitors (TKIs) have become standard of care in patients with EGFR
mutations in non-small cell lung cancer and other EGFR-mutated cancers. However, TKIs are
well-known to cause cutaneous adverse events, including acneiform eruptions. Moderate to
severe acneiform eruptions are often associated with severe pruritus and pain. Current
treatment recommendations rely on expert consensus. Moderate and severe reactions requiring
systemic therapy, usually tetracycline antibiotics or isotretinoin. No randomized trial has
compared the relative effectiveness of tetracyclines versus isotretinoin.
The objective of this unblinded, randomized trial is to compare tetracyclines to isotretinoin
for treatment of moderate to severe acneiform eruptions in cancer patients on tyrosine kinase
inhibitors. The primary aim of this clinical trial is to elucidate which systemic treatment
is more effective in clearing acneiform eruptions caused by TKIs. The results of this study
will add to the literature in this field and will aid in developing evidence based clinical
guidelines.